Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncogene

• Publication date

  2018-03-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41388-018-0200-9PMID 29551769
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The proteasome deubiquitinase inhibitor b-AP15 enhances DR5 activation-induced apoptosis through stabilizing DR5

  2017cited by this paper
• Ginsenoside compound K sensitizes human colon cancer cells to TRAIL-induced apoptosis via autophagy-dependent and -independent DR5 upregulation

  2016cited by this paper
• Macrophage-derived MCPIP1 mediates silica-induced pulmonary fibrosis via autophagy

  2016cited by this paper
• Hepatitis B virus–triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response

  2016cited by this paper
• MCPIP1 Selectively Destabilizes Transcripts Associated with an Antiapoptotic Gene Expression Program in Breast Cancer Cells That Can Elicit Complete Tumor Regression.

  2016influential reference
• Spatial dynamics of TRAIL death receptors in cancer cells.

  2015cited by this paper
• Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells.

  2015cited by this paper
• Targeting TRAIL in the treatment of cancer: new developments

  2015cited by this paper
• Expression of the monocyte chemotactic protein-1-induced protein 1 decreases human neuroblastoma cell survival.

  2014cited by this paper
• Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5

  2013cited by this paper
• Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation.

  2013cited by this paper
• Endocytosis and cancer.

  2013cited by this paper
• Inflammation, Endoplasmic Reticulum Stress, Autophagy, and the Monocyte Chemoattractant Protein-1/CCR2 Pathway

  2012cited by this paper
• MCP-1-induced protein-1, an immune regulator

  2012cited by this paper
• Monocyte chemotactic protein-1-induced protein-1 (MCPIP1) is a novel multifunctional modulator of inflammatory reactions.

  2012cited by this paper
• MCPIP1 ribonuclease antagonizes dicer and terminates microRNA biogenesis through precursor microRNA degradation.

  2011cited by this paper
• Autophagy as a target for anticancer therapy

  2011cited by this paper
• Monocyte Chemotactic Protein-induced Protein 1 (MCPIP1) Suppresses Stress Granule Formation and Determines Apoptosis under Stress*

  2011cited by this paper
• Retinoic acid enhances TRAIL-induced apoptosis in cancer cells by upregulating TRAIL receptor 1 expression.

  2011cited by this paper
• Osteoclast precursor differentiation by MCPIP via oxidative stress, endoplasmic reticulum stress, and autophagy.

  2011cited by this paper
• Oncogenic Ras and B-Raf Proteins Positively Regulate Death Receptor 5 Expression through Co-activation of ERK and JNK Signaling*

  2011cited by this paper
• Death Receptor 5 Internalization is Required for Lysosomal Permeabilization by TRAIL in Malignant Liver Cell Lines

  2010cited by this paper
• c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL

  2010cited by this paper
• MCP-induced protein 1 deubiquitinates TRAF proteins and negatively regulates JNK and NF-κB signaling

  2010cited by this paper
• MCP-1 causes cardiomyoblast death via autophagy resulting from ER stress caused by oxidative stress generated by inducing a novel zinc-finger protein, MCPIP.

  2010cited by this paper
• c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance.

  2010cited by this paper
• New insights into apoptosis signaling by Apo2L/TRAIL

  2010cited by this paper
• Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation.

  2010cited by this paper
• ERK/Ribosomal S6 Kinase (RSK) Signaling Positively Regulates Death Receptor 5 Expression through Co-activation of CHOP and Elk1*

  2010cited by this paper
• TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges.

  2009cited by this paper
• TRAIL and other TRAIL receptor agonists as novel cancer therapeutics.

  2009cited by this paper
• Zc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay

  2009cited by this paper
• Death receptor 5 internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines.

  2009cited by this paper
• TRAIL induces endocytosis of its death receptors in MDA-MB-231 breast cancer cells

  2009cited by this paper
• Following TRAIL’s path in the immune system

  2009influential reference
• TRAIL Resistance of Breast Cancer Cells Is Associated with Constitutive Endocytosis of Death Receptors 4 and 5

  2008cited by this paper
• The Farnesyltransferase Inhibitor Lonafarnib Induces CCAAT/Enhancer-binding Protein Homologous Protein-dependent Expression of Death Receptor 5, Leading to Induction of Apoptosis in Human Cancer Cells*

  2007cited by this paper
• Apo2L/TRAIL and immune regulation.

  2007cited by this paper
• Sensitizing tumor cells to immune-mediated cytotoxicity.

  2007cited by this paper
• Death-receptor activation halts clathrin-dependent endocytosis

  2006cited by this paper
• Monocyte Chemoattractant Protein-1 Induces a Novel Transcription Factor That Causes Cardiac Myocyte Apoptosis and Ventricular Dysfunction

  2006influential reference
• Nature's TRAIL--on a path to cancer immunotherapy.

  2003cited by this paper

• MCPIP1 Controls Hybrid EMT and Tumor Stemness via the IL6/JAK2/STAT3 Axis in Pancreatic Cancer

  2025cites this paper
• ZC3H12A: A Critical Mediator of Inflammation, Tumor Immunotherapy, and Metabolic–Immune Crosstalk—Implications for Disease Treatment

  2025cites this paper
• MCPIP1 functions as a safeguard of early embryonic development

  2023cites this paper
• Targeting deubiquitinases for cancer therapy

  2023cites this paper
• Krüppel-like factors in tumors: Key regulators and therapeutic avenues

  2023cites this paper
• ZNF33A promotes tumor progression and BET inhibitor resistance in triple-negative breast cancer.

  2022cites this paper
• Regulation of Cancer Metastasis by TRAIL/Death Receptor Signaling

  2021cites this paper
• How are MCPIP1 and cytokines mutually regulated in cancer-related immunity?

  2020cites this paper
• E3 ubiquitin ligases and deubiquitinases as modulators of TRAIL-mediated extrinsic apoptotic signaling pathway

  2019cites this paper
• Activity of MCPIP1 RNase in tumor associated processes

  2019cites this paper
• Regulatory interplay between deubiquitinating enzymes and cytokines

  2019influential citation
• CCL2 promotes macrophages-associated chemoresistance via MCPIP1 dual catalytic activities in multiple myeloma

  2019cites this paper
• Natural Product Mediated Regulation of Death Receptors and Intracellular Machinery: Fresh from the Pipeline about TRAIL-Mediated Signaling and Natural TRAIL Sensitizers

  2019cites this paper
• MCPIP1 regulates RORα expression to protect against liver injury induced by lipopolysaccharide via modulation of miR‐155

  2019cites this paper
• Involvement of ERK1/2-mediated ELK1/CHOP/DR5 pathway in 6-(methylsulfinyl)hexyl isothiocyanate-induced apoptosis of colorectal cancer cells

  2019cites this paper
• EFFECTS OF ANESTHESIA ON INNATE IMMUNE COMPONENTS IN ORTHOPEDIC SURGERY

  2018cites this paper
• Garcinol Enhances TRAIL-Induced Apoptotic Cell Death through Up-Regulation of DR5 and Down-Regulation of c-FLIP Expression

  2018cites this paper